BPMC – Blueprint Medicines Corporation
Blueprint Medicines CorporationBPMC
$92.25Name : Blueprint Medicines Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $5,895,328,256.00
EPSttm : -1.07
Blueprint Medicines Corporation
$92.25
2.23%$2.10Float Short %
6.75
Margin Of Safety %
Put/Call OI Ratio
0.98
EPS Next Q Diff
0.32
EPS Last/This Y
EPS This/Next Y
2.69
Price
92.25
Target Price
126.79
Analyst Recom
1.71
Performance Q
2.3
Relative Volume
0.92
Beta
0.55
Ticker: BPMC
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | BPMC | 115.78 | 0.89 | 2.04 | 30392 |
| 2025-01-24 | BPMC | 114.98 | 1.10 | 0.44 | 36767 |
| 2025-01-27 | BPMC | 113.97 | 1.07 | 0.07 | 37407 |
| 2025-01-28 | BPMC | 114.5 | 1.07 | 0.06 | 37404 |
| 2025-01-29 | BPMC | 114.44 | 1.06 | 0.13 | 37522 |
| 2025-01-30 | BPMC | 114.04 | 1.02 | 1.65 | 38620 |
| 2025-01-31 | BPMC | 112.46 | 1.03 | 0.37 | 39254 |
| 2025-02-03 | BPMC | 111.5 | 1.01 | 0.06 | 40099 |
| 2025-02-04 | BPMC | 113.42 | 0.99 | 0.76 | 40681 |
| 2025-02-05 | BPMC | 110.44 | 0.98 | 0.05 | 40734 |
| 2025-02-06 | BPMC | 109.58 | 0.98 | 0.27 | 40905 |
| 2025-02-07 | BPMC | 104.99 | 0.97 | 0.01 | 41255 |
| 2025-02-10 | BPMC | 103.93 | 0.93 | 0.02 | 42180 |
| 2025-02-11 | BPMC | 101.57 | 0.88 | 0.46 | 43313 |
| 2025-02-12 | BPMC | 103.6 | 0.88 | 0.15 | 43490 |
| 2025-02-13 | BPMC | 95.26 | 0.87 | 1.15 | 44068 |
| 2025-02-14 | BPMC | 94 | 0.89 | 0.10 | 45149 |
| 2025-02-18 | BPMC | 92.43 | 0.89 | 0.03 | 45138 |
| 2025-02-19 | BPMC | 94.15 | 0.99 | 0.33 | 42852 |
| 2025-02-20 | BPMC | 94.36 | 0.99 | 0.03 | 43023 |
| 2025-02-21 | BPMC | 92.28 | 0.98 | 1.17 | 43211 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | BPMC | 115.63 | 63.4 | 104.5 | -1.40 |
| 2025-01-24 | BPMC | 114.96 | 63.4 | 103.8 | -1.40 |
| 2025-01-27 | BPMC | 113.99 | 63.4 | 103.8 | -1.40 |
| 2025-01-28 | BPMC | 114.47 | 63.4 | 104.0 | -1.40 |
| 2025-01-29 | BPMC | 114.35 | 63.4 | 103.9 | -1.40 |
| 2025-01-30 | BPMC | 114.05 | 61.8 | 103.9 | -1.40 |
| 2025-01-31 | BPMC | 112.38 | 61.8 | 103.7 | -1.40 |
| 2025-02-03 | BPMC | 111.50 | 61.8 | 103.8 | -1.40 |
| 2025-02-04 | BPMC | 113.38 | 61.8 | 104.2 | -1.40 |
| 2025-02-05 | BPMC | 110.34 | 61.8 | 103.5 | -1.40 |
| 2025-02-06 | BPMC | 109.67 | 61.8 | 103.8 | -1.40 |
| 2025-02-07 | BPMC | 104.97 | 61.8 | 103.3 | -1.40 |
| 2025-02-10 | BPMC | 104.00 | 61.8 | 103.8 | -1.40 |
| 2025-02-11 | BPMC | 101.48 | 61.8 | 103.5 | -1.40 |
| 2025-02-12 | BPMC | 103.65 | 61.8 | 104.2 | -1.40 |
| 2025-02-13 | BPMC | 95.26 | 61.8 | 102.7 | -1.40 |
| 2025-02-14 | BPMC | 93.94 | 61.8 | 103.7 | -0.81 |
| 2025-02-18 | BPMC | 92.43 | 74.4 | 11.3 | -1.28 |
| 2025-02-19 | BPMC | 94.07 | 74.4 | -54.4 | -1.28 |
| 2025-02-20 | BPMC | 94.31 | 74.4 | -53.6 | -1.28 |
| 2025-02-21 | BPMC | 92.25 | 74.4 | -52.3 | -1.28 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | BPMC | -9.07 | -1.46 | 8.19 |
| 2025-01-24 | BPMC | -10.29 | -1.46 | 8.19 |
| 2025-01-27 | BPMC | -10.29 | -1.51 | 8.19 |
| 2025-01-28 | BPMC | -10.39 | -1.51 | 8.26 |
| 2025-01-29 | BPMC | -10.39 | -1.51 | 8.26 |
| 2025-01-30 | BPMC | -10.39 | -1.51 | 8.26 |
| 2025-01-31 | BPMC | -10.39 | -1.51 | 8.26 |
| 2025-02-03 | BPMC | -10.39 | -1.02 | 8.26 |
| 2025-02-04 | BPMC | -10.39 | -1.02 | 8.26 |
| 2025-02-05 | BPMC | -10.39 | -1.02 | 8.26 |
| 2025-02-06 | BPMC | -10.39 | -1.02 | 8.26 |
| 2025-02-07 | BPMC | -10.39 | -1.02 | 8.26 |
| 2025-02-10 | BPMC | -7.60 | -0.38 | 8.29 |
| 2025-02-11 | BPMC | -6.45 | -0.38 | 8.29 |
| 2025-02-12 | BPMC | -6.45 | -0.38 | 6.79 |
| 2025-02-13 | BPMC | -6.45 | -0.38 | 6.79 |
| 2025-02-14 | BPMC | -7.53 | -0.38 | 6.77 |
| 2025-02-18 | BPMC | -7.49 | -1.28 | 6.73 |
| 2025-02-19 | BPMC | -6.31 | -1.28 | 6.75 |
| 2025-02-20 | BPMC | -6.05 | -1.28 | 6.75 |
| 2025-02-21 | BPMC | -6.08 | -1.28 | 6.75 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.79
Avg. EPS Est. Current Quarter
-0.34
Avg. EPS Est. Next Quarter
-0.47
Insider Transactions
-6.08
Institutional Transactions
-1.28
Beta
0.55
Average Sales Estimate Current Quarter
160
Average Sales Estimate Next Quarter
176
Fair Value
Quality Score
49
Growth Score
56
Sentiment Score
43
Actual DrawDown %
26.6
Max Drawdown 5-Year %
-69.5
Target Price
126.79
P/E
Forward P/E
77.49
PEG
P/S
11.59
P/B
19.68
P/Free Cash Flow
EPS
-1.07
Average EPS Est. Cur. Y
-1.28
EPS Next Y. (Est.)
1.41
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
-13.19
Relative Volume
0.92
Return on Equity vs Sector %
-41.7
Return on Equity vs Industry %
-26.1
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.35
EBIT Estimation
-52.3
Blueprint Medicines CorporationSector: Healthcare
Industry: Biotechnology
Employees: 649
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
stock quote shares BPMC – Blueprint Medicines Corporation Stock Price stock today
news today BPMC – Blueprint Medicines Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch BPMC – Blueprint Medicines Corporation yahoo finance google finance
stock history BPMC – Blueprint Medicines Corporation invest stock market
stock prices BPMC premarket after hours
ticker BPMC fair value insiders trading